Gapping down
Briefing note: With US Futures down ~1.5% in pre-mkt, most stocks are trading lower. The following represents stocks lower on more specific items.In reaction to disappointing earnings/guidance: IBM -6%, AMD -4.6%, EAT -4.6%, IBKR -4.4%, RDS.A -3.7%, PACB -2.7%, GS -1.6%
Select financial related names showing weakness: HSBC -3.8%, CS -3.8%, DB -3.3%, BAC -3.3%, BCS -3.2%, C -2.9%, ING -2.7%, LYB -2.7%, JPM -2.3%
Select oil/gas related names showing early weakness: WLL -9.7%, LEI -8.1%, DVN -5.8%, CHK -5.2%, PBR -4.7%, STO -4.2%, TOT -3.2%, APC -2.9%, SLB -2.9%
Other news: THS -7.8% (to offer up to $750 mln in common stock to fund part of its acquisition of ConAgra's (CAG) Private Brands business), SUNE -6.5% (still checking), BHP -6% (reported FY15 op metrics), DOC -5.7% (upsizes and prices 18.5 mln shares of common stock at $15.75), AMD -5.6% (following IBM results), MU -4.3% (following IBM results), SSS -3.5% ( commences a public offering of 2.3 mln shares of common stock), BABA -3.3% (weakness in Chinese mkts overnight), BIDU -2.7% (weakness in Chinese mkts overnight)
Analyst comments: SDRL -10.8% (downgraded to Underperform at BofA/Merrill), FTNT -6.7% (downgraded to Neutral from Overweight at Piper Jaffray), VALE -6% (downgraded to Hold from Buy at HSBC Securities), RACE -2.2% (initiated with a Neutral at Citigroup; tgt $37), TIF -2% (downgraded to Neutral from Buy at Goldman), PRU -1.9% (downgraded to Neutral from Buy at BofA/Merrill)
Gapping up
In reaction to strong earnings/guidance: GNC +14.6%, CLMT +5%, AMTD +2%, CREE +1.7%, ASML +1.7%, LLTC +1.6%, NLS +1.5%, ADTN +1.5%, TEL +0.8%, APH +0.7%
Select gold mining stocks trading higher: HMY +9.3%, IAG +5.2%, HL +3.3%, ABX +3%, GG +2.8%, GFI +2.5%, NEM +2.4%, AEM +2%, GLD +1.2%
Other news: ZFGN +37% ( positive efficacy results from the bestPWS ZAF-311 Phase 3 trial), SYN +21.7% (The second Phase 2 clinical trial of SYN-010 for the treatment of irritable bowel syndrome with constipation met its primary endpoint), CBAY +17.3% (Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate), SFUN +5.5% (made significant progress on acquisition of controlling stake in Chongqing Wanli New Energy), PESI +5.1% (part of winning team led by CH2M Hill selected by US Navy for a $240 mln, 5-year Comprehensive Long-Term Environmental Action Navy (CLEAN) contract), CLMT +5% (declared $0.685 dividend, unchanged from prior dividend; reaffirmed objective of providing all unitholders a stable-to-growing quarterly cash distribution), SCS +2.1% (Board approved a $150 mln increase to its share repurchase program)
Analyst comments: BSFT +2% (upgraded to Outperform from Market Perform at Wells Fargo)
- Reports Q4 (Dec) earnings of $4.68 per share, may not be comparable to the Capital IQ Consensus of $3.62; revenues fell 5.5% year/year to $7.27 bln vs the $7.04 bln Capital IQ Consensus.
- Diluted earnings per common share were $1.27 compared with $4.38 for the fourth quarter of 2014 and $2.90 for the third quarter of 2015. During the fourth quarter of 2015, the firm recorded provisions for the settlement with the RMBS Working Group (1) of $1.80 billion ($1.54 billion after-tax), which reduced diluted earnings per common share by $3.41 and annualized ROE by 8.1 percentage points.The $4.68 figure does include CVA/DVA
- Annualized ROE as 3.0% for the fourth quarter of 2015.
-
Investment Banking
- Net revenues in Investment Banking were $1.55 billion for Q4, 7% higher y/y.
- Net revenues in Financial Advisory were $879 million, 27% higher y/y.
- Net revenues in Underwriting were $668 million, 11% lower y/y.
-
Institutional Client Services
- Net revenues in Institutional Client Services were $2.88 billion for the fourth quarter of 2015, 9% lower y/y.
- Net revenues in Fixed Income, Currency and Commodities Client Execution were $1.12 billion for the fourth quarter of 2015, 8% lower y/y.
- Net revenues in Equities were $1.76 billion for the fourth quarter of 2015, 9% lower y/y.
- The fair value net loss attributable to the impact of changes in the firm's credit spreads on borrowings was $68 million.
-
Investing & Lending
- Net revenues in Investing & Lendingwere $1.30 billion for the fourth quarter of 2015, 15% lower y/y.
-
Investment Management
- Net revenues in Investment Management were $1.55 billion for the fourth quarter of 2015, essentially unchanged compared with the fourth quarter of 2014 and 9% higher than the third quarter of 2015.
-
Noncomp Expenses
- Non-compensation expenses were $4.14 billion for the fourth quarter of 2015, 64% higher y/y. The increase compared with the fourth quarter of 2014 was due to significantly higher net provisions for mortgage-related litigation and regulatory matters, which are included in other expenses.
- Net provisions for litigation and regulatory proceedings for the fourth quarter of 2015 were $1.95 billion compared with $161 million for the fourth quarter of 2014 (both primarily comprised of net provisions for mortgage-related matters).
- Book value per common share was $171.03 and tangible book value per common share was $161.64, both 5% higher compared with the end of 2014 and essentially unchanged compared with the end of the third quarter of 2015.
Gapping down: SDRL -11.8%, CHK -9.1%, VALE -8.6%, DDD -7.1%, BBL-6.8%, SUNE -6.5%, DVN -6.3%, BHP -6.2%, DOC -5.7%, FTNT -5.5%, SYMC-5.3%, MT -5.1%, AMD -5.1%, PBR -5%, DB -4.6%, HSBC -4.6%, IBM -4.6%,FCX -4.5%, MU -4.4%, IBKR -4.4%, RDS.A -4.4%, APC -4.3%, STO -4.2%, CS-3.9%, JOY -3.7%, BAC -3.7%, SLB -3.5%, TWTR -3.5%, C -3.4%, TOT -3.4%,AEG -3.4%, SSS -3%, BIDU -2.9%, BABA -2.9%, BCS -2.9%, JPM -2.7%, ING-2.7%, LYB -2.7%, RACE -2.6%